Skip to main content

Cellular Therapies and Outpatient Care: from the Basics to Clinics

243kviews

ORIGINAL RESEARCH

18 June 2025

Using technology for patient-centered care at home after CAR T-cell therapy or stem cell transplant: a prospective feasibility study

Susan L. Moore, 6 more and Clayton A. Smith

4,137 views

7 citations

ORIGINAL RESEARCH

4 October 2024

A comparison of haploidentical versus HLA-identical sibling outpatient hematopoietic cell transplantation using reduced intensity conditioning in patients with acute leukemia

José Carlos Jaime-Pérez, 6 more and David Gómez-Almaguer

4,373 views

7 citations

CASE REPORT

20 September 2024

Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen

Raya Aliakbar, 7 more and Xenos L. Mason

5,310 views

10 citations

ORIGINAL RESEARCH

21 August 2024

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4

Doris K. Hansen, 8 more and Sundar Jagannath

9,055 views

12 citations

ORIGINAL RESEARCH

14 June 2024

Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin’s lymphoma

David G. Frame, 16 more and Monalisa Ghosh

5,139 views

9 citations

SYSTEMATIC REVIEW

16 July 2024

Ambulatory models for autologous stem-cell transplantation: a systematic review of the health impact

Miguel Ángel Prieto del Pradoand Francesc Fernández Avilés

4,820 views

7 citations

PERSPECTIVE

11 June 2024

Optimization of a home hospitalization program for hematopoietic stem cell transplantation with ehealth integration and clinical pharmacist involvement

Maria-Estela Moreno-Martinez, 12 more and Anna Feliu

3,415 views

6 citations

REVIEW

6 August 2024

Policy and perspective on outpatient programs for autologous hematopoietic cell transplantation and immune-effector cell therapy administration

Scott R. Goldsmith, 3 more and Michael Rosenzweig

3,025 views

2 citations

ORIGINAL RESEARCH

10 June 2024

Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma

Doris K. Hansen, 15 more and Krina K. Patel

6,471 views

7 citations

ORIGINAL RESEARCH

24 May 2024

Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States

Olalekan O. Oluwole, 5 more and S. Pinar Bilir

8,248 views

8 citations

MINI REVIEW

8 May 2024

Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers

Ariel Perez, 2 more and Yuliya P. L. Linhares

8,941 views

13 citations

MINI REVIEW

26 April 2024

Brave new world: expanding home care in stem cell transplantation and advanced therapies with new technologies

Iñigo Romon, 3 more and Isabel Sampedro

4,073 views

5 citations

REVIEW

5 October 2023

Novel therapies for graft versus host disease with a focus on cell therapies

Robert Zeiser, 3 more and Oscar G. Segurado

10,550 views

30 citations

CASE REPORT

2 October 2023

Case Report: Fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up

Jiali Cheng, 6 more and Na Wang

4,290 views

9 citations

From bench to bedside: the history and progress of CAR T cell therapy

REVIEW

15 May 2023

From bench to bedside: the history and progress of CAR T cell therapy

Aroshi Mitra, 4 more and Bin He

163,937 views

502 citations

Due to the hospitals’ aggressive microorganism environment, standard bone marrow transplantations (BMTs) are currently performed in air-filtered positive-pressured isolation rooms. In an attempt to reduce the risk of infection while improving patients’ well-being during the early phase, transplant centers have developed alternative outpatient and home care models.

As a result, transplant-related complications have diminished in incidence, and hospital bed capacity has been optimized. However, differences arise when distinct ambulatory care models are compared. Furthermore, the best approach to delivering care in these settings is not established.

For autologous BMT, advantages in neutropenic fever (NF) and infection rates have only been described in-home care (HC) models, with comparable results between outpatient (OC) and hospital care. Reduction in costs (19.32%-46.48%) has been reported in-home and outpatient models for this type of cellular therapy.

In the context of allogeneic BMT, reduced NF and infection rates, total parenteral nutrition requirements, non-relapse mortality, and costs have been associated with both OC and HC models, but only HC has been associated with a reduction in grade II-IV acute GVHD (17% vs. 44%, p<0.01) and superior overall survival (63% vs. 44% at 4 years, p=0.04), when compared to hospital care.

With respect to GVHD prophylactic regimes, the current shift in practice towards T-cell depletion (TCD) has only been tested outside hospitals in outpatient models, while the combination of TCD and HC is still formally unexplored and limited to a handful of articles with poor representation of in vivo TCD.

Regarding chimeric antigen receptor T (CAR T) cells and OC, CD19 CAR T-cell pivotal trials for non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL) included patients treated in full-outpatient programs (26% in JULIET, 9% in TRANSCEND and 24% in ELIANA) or early discharge policies (minimum of 7-day hospital stay in ZUMA-1).

To make CAR T cells financially sustainable for healthcare systems, implementation of internal policies that alleviate costs, like HC programs, has become a relevant and active topic, even more now seen their fast approval in second-line large B-cell lymphoma and in relapsed/refractory multiple myeloma. However, real-world data is still limited.

We seek translational research that clarifies the underlying biology of these models’ observed benefits, as well as clinical research that improves care strategies, patient selection, prognostic stratification (ex. biomarkers), and the feasibility of these models. Technological innovations and discussions about current healthcare policies are under the scope of this collection.

Accepted Articles: Clinical trials, study protocols, original research, systematic reviews, reviews, mini-reviews, perspectives, brief research reports, hypothesis and theory, opinion, perspectives, curriculum, instruction and pedagogy, policy brief, and technology and code articles.

Studies should focus on, although not strictly limited to, the following topics:
- Strategies to implement or improve HC programs.
- Healthcare team, patients, and caregivers’ educational policies.
- Risk stratification and patient selection: biomarkers and prognostic tools.
- Cellular therapies-related complications: clinical-biological differences considering the setting (home vs. hospital care).
- Nutrition and microbiome.
- Infections.
- Innovations in technology.
- Health care policies.

Download ebook

Share

243,247 Total views
184,225 Article views
52,534 Article downloads
6,488 Topic views

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic